A Tumor‐Specific Cascade Amplification Drug Release Nanoparticle for Overcoming Multidrug Resistance in Cancers. Issue 38 (21st August 2017)

• Record Type: Journal Article
• Authors: Ye, Mingzhou; Han, Yuxin; Tang, Jianbin; Piao, Ying; Liu, Xiangrui; Zhou, Zhuxian; Gao, Jianqing; Rao, Jianghong; Shen, Youqing
• Is Part Of: Advanced materials. Volume 29:Issue 38(2017)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2017-08-21
• Subjects: β‐lapachone -- anticancer prodrug -- cascade amplification drug release -- drug delivery -- multidrug resistance; Materials -- Periodicals; Chemical vapor deposition -- Periodicals; 620.11
• DOI: 10.1002/adma.201702342
• Languages: English
• ISSNs: 0935-9648

Abstract

Abstract : A cascade amplification release nanoparticle (CARN) is constructed by the coencapsulation of β‐lapachone and a reactive‐oxygen‐species (ROS)‐responsive doxorubicin (DOX) prodrug, BDOX, in polymeric nanoparticles. Releasing β‐lapachone first from the CARNs selectively increases the ROS level in cancer cells via NAD(P)H:quinone oxidoreductase‐1 (NQO1) catalysis, which induces the cascade amplification release of DOX and overcomes multidrug resistance (MDR) in cancer cells, producing a remarkably improved therapeutic efficacy against MDR tumors with minimal side effects. Abstract : A cascade amplification release nanoparticle is constructed by loading β‐lapachone and a reactive‐oxygen‐species‐responsive doxorubicin (DOX) prodrug in polymeric nanoparticles. The selective cascade amplification release of β‐lapachone and DOX in cancer cells remarkably increases the selectivity of chemotherapy and overcomes the multidrug resistance (MDR) in cancer cells, producing a remarkably enhanced therapeutic efficacy against MDR tumors with minimal side effects.